AR034398A1 - Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento - Google Patents

Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento

Info

Publication number
AR034398A1
AR034398A1 ARP000105872A ARP000105872A AR034398A1 AR 034398 A1 AR034398 A1 AR 034398A1 AR P000105872 A ARP000105872 A AR P000105872A AR P000105872 A ARP000105872 A AR P000105872A AR 034398 A1 AR034398 A1 AR 034398A1
Authority
AR
Argentina
Prior art keywords
free
functionally modified
pharmaceutically acceptable
same
hete
Prior art date
Application number
ARP000105872A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR034398A1 publication Critical patent/AR034398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/60—Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se revelan homólogos del 15-hete con 3-heteroátomos sustituidos y dos átomos de carbono del ácido hidroxieicosatetraenoico, que comprenden un compuesto de la fórmula (1), en la cual: R1 es (CH2)n-CO2R, (CH2)nCONR2R3, (CH2)nCH2OR4, (CH2)nCH2NR5R6, (CH2)nCH2N3, (CH2)CH2Hal, (CH2)nCH2NO2, (CH2)nCH2SR20, (CH2)nCOSR21 o (CH2)n-2,3,4,5-tetrazol-1-ilo, en lo cual R representa H, o CO2R forma una sal farmacéuticamente aceptable o un éster farmacéuticamente aceptable; NR2R3 y NR5R6, que son iguales o diferentes, comprenden un grupo amino libre o funcionalmente modificado; OR4 comprende un grupo hidroxi libre o funcionalmente modificado; Hal es F, Cl, Br o I; SR20 comprende un grupo tiol libre o funcionalmente modificado; R21 es H, o COSR21 forma una sal farmacéuticamente aceptable o un tioéster farmacéuticamente aceptable; n vale 0 o 2; X es O, S(O)p, NR7 o CH2, con la condición que X no puede ser CH2 cuando n = 0; p vale 0, 1 o 2; NR7 comprende un grupo amino libre o funcionalmente modificado; A - B, D - E, G - T y J - K, que son iguales o diferentes, son: CH2CH2, CH=CH o C ::: C, con la condición que por lo menos uno de los siguientes: A - B, D - E, G - T y J - K; debe ser CH = CH o C ::: C; e Y es C(O) (es decir, un carbonilo), o Y es fórmula (2) o (3) en lo cual R9O constituye un grupo hidroxi libre o funcionalmente modificado; con la condición que queda excluido el compuesto de la fórmula (4), composición que los contiene y el uso de la misma para la manufactura de un medicamento oftálmico.
ARP000105872A 1999-11-09 2000-11-08 Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento AR034398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16436899P 1999-11-09 1999-11-09

Publications (1)

Publication Number Publication Date
AR034398A1 true AR034398A1 (es) 2004-02-25

Family

ID=22594175

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105872A AR034398A1 (es) 1999-11-09 2000-11-08 Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento

Country Status (12)

Country Link
US (2) US6331644B1 (es)
EP (1) EP1228027B1 (es)
JP (1) JP2003513948A (es)
AR (1) AR034398A1 (es)
AT (1) ATE265996T1 (es)
AU (1) AU776146B2 (es)
CA (1) CA2386333A1 (es)
DE (1) DE60010503T2 (es)
DK (1) DK1228027T3 (es)
ES (1) ES2215740T3 (es)
PT (1) PT1228027E (es)
WO (1) WO2001034548A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776146B2 (en) * 1999-11-09 2004-08-26 Alcon Inc. 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use
EP1438037A1 (en) * 2001-10-11 2004-07-21 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
US20030109508A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
AU2003221707A1 (en) * 2002-06-14 2003-12-31 Alcon, Inc. Topical use of hydroxyeicosatetraenoic acid compounds to treat psoriasis
EP1583527A1 (en) * 2002-06-14 2005-10-12 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
PL374700A1 (en) * 2002-09-20 2005-10-31 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
AU546872B2 (en) 1982-06-16 1985-09-26 Unilever Plc Skin treatment compositions containing a fatty acid or ester
US4421748A (en) 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US4921644A (en) 1988-02-29 1990-05-01 Technology Unlimited, Inc. Mucin directed lipsome
US4906467A (en) 1988-03-24 1990-03-06 New York Medical College Novel, long-duration treatment for glaucoma
US4923700A (en) 1988-06-03 1990-05-08 Kaufman Herbert E Artificial tear suspension
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
AU655919B2 (en) 1990-02-22 1995-01-19 Macnaught Pty Limited Artificial tears
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
EP0546728A3 (en) 1991-12-13 1993-09-08 Alcon Laboratories Inc Physiological tear compositions and methods for their preparation
AU674681B2 (en) 1992-04-21 1997-01-09 Schepens Eye Research Institute, Inc., The Ocular androgen therapy in Sjogren's syndrome
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5358706A (en) 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
WO1994021595A1 (en) * 1993-03-17 1994-09-29 Kao Corporation Amine derivative and dermatologic preparation containing the same
US5389383A (en) 1993-06-18 1995-02-14 Allergan, Inc. Method for treating hypoxia-associated ocular complications
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
DK0964690T3 (da) 1996-10-15 2003-10-20 Liposome Co Inc Peptid-lipidkonjugater, liposomer og liposomal lægemiddeladministration
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6281192B1 (en) 1999-03-01 2001-08-28 Vista Scientific Llc Mucin containing ophthalmic preparations
AU776146B2 (en) * 1999-11-09 2004-08-26 Alcon Inc. 3-heteroatom substituted and two carbon homologs of 15-HETE and methods of use

Also Published As

Publication number Publication date
AU1101101A (en) 2001-06-06
US6331644B1 (en) 2001-12-18
DE60010503T2 (de) 2004-09-23
WO2001034548A2 (en) 2001-05-17
JP2003513948A (ja) 2003-04-15
US6437160B1 (en) 2002-08-20
ES2215740T3 (es) 2004-10-16
EP1228027A2 (en) 2002-08-07
PT1228027E (pt) 2004-08-31
US20020082286A1 (en) 2002-06-27
AU776146B2 (en) 2004-08-26
EP1228027B1 (en) 2004-05-06
DK1228027T3 (da) 2004-07-19
WO2001034548A3 (en) 2001-11-01
DE60010503D1 (de) 2004-06-09
CA2386333A1 (en) 2001-05-17
ATE265996T1 (de) 2004-05-15

Similar Documents

Publication Publication Date Title
MX2021001906A (es) Metodos para reducir la necesidad de revascularizacion arterial periferica en un sujeto tratado con estatinas.
LU90230I2 (fr) Cerivastatine (INN) et ses sels et dérivés pharmaceutiquement acceptables (LIPOBAY )
ES2094350T3 (es) Cromano y tiocromanos con sustituyentes de feniletinilo en la posicion 7 que tienen actividad biologica de tipo retinoide.
ATE191143T1 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
FI914905A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi
ATE226821T1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
DE69229442T2 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
HUP0101640A2 (hu) Endotelinkonvertáló enzimet gátló tiolvegyületek
DK0977560T3 (da) Ibuprofen-thioestere som hæmmere af den Nf-kappaB-afhængige dannelse af betændelses og smertemediatorer (CoA-thioestere af arylpropionsyrer, aryleddikesyrer og salicylater som hæmmere af den Nf-kappaB-afhængige dannelse af betændelses og smertemediatorer)
AR034398A1 (es) Homologos de 15-hete con 3-heteroatomos sustituidos y dos atomos de carbono del acido hidroxieicosatetraenoico, composicion que los contiene y el uso de la misma para la manufactura de un medicamento
AU1911999A (en) Methods and compositions for treating diabetes
DE3586935T2 (de) Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
ES2148305T3 (es) Derivados de aminoacidos ciclicos que tienen actividad inhibidora de ace y nep.
AR031536A1 (es) Analogos heteroatomo- interrumpidos del acido 15-hidroxieicosatetraenoico, composicion que lo comprende y el uso de los mismos para la manufactura de un medicamento
DK562488D0 (da) Farmaceutisk praeparat indeholdende polyminderivater, samt nogle af disse polyaminderivater
KR880009934A (ko) 피리딘-2,4-및 2,5-디카복실산 유도체, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제
EA200300436A1 (ru) Производные триптамина и аналогичные соединения и содержащие их фармацевтические композиции
DE60231047D1 (de) Verfahren zur unterdrückung oder umkehrung der tau-filament-bildungspolymerisation
NO932843L (no) Farmasoeytiske preparater
ES2041815T3 (es) Un procedimiento para la obtencion de derivados de ornitina 5-sustituidos.
PT643061E (pt) Novos antibioticos de cefalosporina e processos para a sua preparacao
AR042295A1 (es) Sales fumarato cristalinas de furo [ 2,3- c ] piridinilcarboxamida sustituida con 1- azabiciclo [ 2. 2. 2 ] octilo y composiciones y preparaciones de las mismas
ES554827A0 (es) Procedimiento para preparar acidos hexenoicos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure